Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis

Stroke

Volumn 29, Issue 12, 1998, Pages 2478-2483

  Yoo, Jun Hyun ^a,b   Chung, Chin Sang ^a,b   Kang, Soo Sang ^c  

^a Samsung Medical Center   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c RUSH MEDICAL COLLEGE   (United States)

Author keywords

Atherosclerosis; Cerebral arteries; Cerebral infarction; Homocyst(e)ine

Indexed keywords

CHOLESTEROL; HOMOCYSTEINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BRAIN ATHEROSCLEROSIS; BRAIN INFARCTION; CASE CONTROL STUDY; CONTROLLED STUDY; HUMAN; HYPERHOMOCYSTEINEMIA; KOREA; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL;

EID: 0031786776     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.29.12.2478     Document Type: Article

References (43)

1. National Statistical Office. Death rates by the causes of death per 100,000 population. In: International Statistics Yearbook. Seoul, Republic of Korea. 1997:7.
2. The Korean Neurological Association. Epidemiology of cerebrovascular disease in Korea. J Korean Med Sci. 1993;8:281-289.
3. Kang S-S, Wong PWK, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr. 1992;12:279-298.
4. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56:111-128.
5. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GHJ, Bromberg IL, Cerone R, Fowler B, Grobe H, Schmidt H, Schweitzer L. The natural history of homocystinuria due to cystathione beta-synthase deficiency. Am J Hum Genet. 1985;37:1-31.
6. Boushey CJ, Shirley AA, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049-1057.
7. Kang S-S, Wong PWK, Cook HY, Norusis M, Messer JV. Protein-bound homocysteine: a possible risk factor for coronary artery disease. J Clin Invest. 1986;77:1482-1486.
8. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A Prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;268:877-881.
9. Kang S-S, Passen EL, Ruggie N, Wong PWK, Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 1993;88:1463-1469.
10. Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, Garmo PD. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke. 1990;21:572-576.
11. Brattström L, Lindgren A, Israelsson B, Malinow MR, Norrving B, Upson B, Hamfelt A. Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors. Eur J Clin Invest. 1992;22:214-221.
12. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A Prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke. 1994;25:1924-1930.
13. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995;346:1395-1398.
14. Mereau-Richard C, Muller JP, Favre E, Ardouin P, Rousseaux J. Total plasma homocysteine determination in subjects with premature cerebral vascular disease. Clin Chem. 1991;37:126. Letter.
15. Lindgren A, Brattstr 246 m L, Norrving B, Hultberg B, Andersson A, Johansson BB. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke. 1995;26:795-800.
16. Evers S, Koch H-G, Grotemeyer K-H, Lange B, Deufel T, Ringelstein E-B. Features, symptoms, and neurophysiological findings in stroke associated with hyperhomocysteinemia. Arch Neurol. 1997;54:1276-1282.
17. Malinow MR, Kang S-S, Taylor LM, Wong PWK, Coull B, Inahara T, Mukerjee D, Sexton G, Upson B. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation. 1989; 79:1180-1188.
18. Molgaard J, Malinow MR, Lassvik C, Holm AC, Upson B, Olsson AG. Hyperhomocyst(e)inaemia: an independent risk factor for intermittent claudication. J Intern Med. 1992;231:273-279.
19. Mainow MR, Nieto JN, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults: the Atherosclerotic Risk in Communities Study. Circulation. 1993;87:1107-1113.
20. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PWF, Belanger AJ, O'Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995;332:286-291.
21. Ubbink JB, Vermaark WJH, Bennett JM, Becker PJ, van Staden DA, Bissbort S. The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease. Klin Wochenschr. 1991;69:527-534.
22. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993;91:308-318.
23. Harker LA, Slichter SJ, Scott CR, Ross R. Homocysteinemia: vascular injury and arterial thrombosis. N Engl J Med. 1974;291:537-543.
24. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, Lee ME. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A. 1994;91: 6369-6373.
25. Di Minno G, Davi G, Margaglione M, Cirillo F, Grandone E, Ciabattoni G, Catalane I, Strisciuglio P, Andria G, Patrono C. Abnormally high thromboxane biosynthesis in homozygous homocystinuria: evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest. 1993;92:1400-1406.
26. Rodgers GM, and Kane WH. Activation of endogenous factor V by a homocysteine induced vascular endothelial cell activator. J Clin Invest. 1986;77:1909-1916.
27. Vester B, and Rasmussen K. High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum. Eur J Clin Chem Clin Biochem. 1991;29:549-554.
28. Araki A, Sako Y, Fukushima Y, Matsumoto M, Asada T, Kita T. Plasma sulfhydryl-containing amino acids in patients with cerebral infarction and in hypertensive subjects. Atherosclerosis. 1989;79:139-146.
29. Yoo J-H. Hyperhomocyst(e)inemia as a Risk Factor of Coronary Artery Disease in Koreans [dissertation]. Seoul, Korea: Seoul National University; 1997.
30. Tchai B-S. Towards securing better nutrition, Korean experience. Nutr Res. 1997;17:1067-1081.
31. Sacco RL, Benjamin FJ, Broderick JP, Dyken M, Easton JD, Feinberg WM, Goldstein LB, Gorelick PB, Howard G, Kitter SJ, Manolio TA, Whisnant JP, Wolf PA. Risk factors. Stroke. 1997;28:1507-1517. AHA Conference Proceedings.
32. Hultberg B, Berglund M, Anderson A, Frank A. Elevated plasma homocysteine in alcoholics. Alcohol Clin Exp Res. 1993;17:687-689.
33. Yoo J-H, Park J-E, Hong K-P, Lee S-H, Kim D-K, Kwon H-C, Lee W-R, Park S-C. The association of moderate hyperhomocyst(e)inemia with coronary artery disease and the severity of coronary atherosclerosis. In: Proceedings of the 2nd international congress on coronary artery disease, October 18-21, 1998, Florence, Italy. Abstract.
34. Tell GS, Crouse JR, Furberg CD. Relation between blood lipids, lipoproteins, and cerebrovascular atherosclerosis: a review. Stroke. 1988; 19:423-430.
35. Uehara T, Mori E, Tabuchi M, Ohsumi Y, Yamadori A. Detection of occlusive lesion in intracranial arteries by three-dimensional time-of-flight magnetic resonance angiography. Cerebrovasc Dis. 1994;4: 365-370.
36. Leung SY, Thomas HK, Yuen ST, Lauder IJ, Faith CS. Pattern of cerebral atherosclerosis in Hong Kong Chinese: severity in intracranial and extracranial vessels. Stroke. 1993;24:779-786.
37. Uehara T, Tabuchi M, Hayashi T, Kurogane H, Yamadori A. Asymptomatic occlusive lesions of carotid and intracranial arteries in Japanese patients with ischemic heart disease: evaluation by brain magnetic resonance angiography. Stroke. 1996;27:393-397.
38. Parthasarathy S. Oxidation of low-density lipoprotein by thiol compounds leads to the recognition by the acetyl LDL receptor. Biochim Biophys Acta. 1987;917:337-340.
39. Starkebaum G, and Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest. 1986;77:1370-1376.
40. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest. 1976;58:731-741.
41. Lipton SA, Kim W-K, Choi Y-B, Kumar S, D'Emilia DM, Rayudu PV, Arnelle DR, Stamler JS. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A. 1997;94:5923-5928.
42. Franken DG, Boers GHJ, Blom HJ, Trijbels FJM, Kloppenborg PWC. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb. 1994;14:465-470.
43. Malinow MR, Nieto FJ, Kruger WD, Duell PB, Hess DL, Gluckman RA, Block PC, Holzkang CR, Anderson PH, Seltzer D, Upson B, Lin QR. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol. 1997;17:1157-1162.